💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

CORRECTED-Ex-Oppenheimer adviser gets six months in U.S. insider trading case

Published 2017-03-15, 09:48 p/m
© Reuters.  CORRECTED-Ex-Oppenheimer adviser gets six months in U.S. insider trading case
PFE
-
RY
-

(Corrects paragraph 6 to say that Michael Maciocio is no longer a Pfizer employee)

By Brendan Pierson

March 15 (Reuters) - A former investment adviser at an Oppenheimer Holdings Inc was sentenced to six months' imprisonment Wednesday after he pleaded guilty to insider trading based on information from a childhood friend working at Pfizer Inc (NYSE:PFE) PFE.N .

David Hobson, 48, was sentenced in federal court in Manhattan by U.S. District Judge Laura Taylor Swain, who recommended Hobson serve his sentence at a halfway house. Hobson was also ordered to forfeit more than $385,000.

Prosecutors had sought a sentence of at least two years.

Prosecutors charged that Hobson, a Providence, Rhode Island resident, began his insider trading in 2008 while working at Royal Bank of Canada RY.TO unit RBC Capital Markets and continued at Oppenheimer & Co Inc OPY.N .

Hobson pleaded guilty to the charges last October. He admitted that he traded on inside information from Michael Maciocio, who at the time was a director of chemical research and development at Pfizer.

Maciocio, who pleaded guilty in May as part of a deal to cooperate with prosecutors, no longer works at Pfizer.

Maciocio's duties included evaluating whether Pfizer would be able to manufacture drugs being developed by other companies that Pfizer might buy or partner with, according to prosecutors.

While Maciocio was not typically told the identities of companies in potential deals, he was often able to identify them through his own research, sometimes with Hobson's help, prosecutors said.

Maciocio then passed the information to Hobson, his stockbroker, who executed trades in accounts belonging to himself, Maciocio, and clients of Oppenheimer and RBC, prosecutors said.

Trades by Hobson in the stocks of Medivation Inc, Ardea Biosciences Inc and Furiex Pharmaceuticals Inc resulted in profits of $165,000 for himself, $40,000 for Maciocio and $150,000 for certain of Hobson's clients, prosecutors said.

The case is U.S. v. Hobson, U.S. District Court, Southern District of New York, No. 16-cr-351.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.